SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

Kiniksa Pharmaceuticals logo
3 weeks ago

Senior Manager, Marketing Operations

Kiniksa Pharmaceuticals

Lexington, MA (On-site)Full time$175K/yr – $195K/yr
Kiniksa Pharmaceuticals logo
3 weeks ago

Associate Director, Digital Marketing

Kiniksa Pharmaceuticals

Lexington, MA (On-site)Full time$175K/yr – $195K/yr
Kiniksa Pharmaceuticals logo
1 month ago

Director, Omnichannel & Marketing Capabilities/AI

Kiniksa Pharmaceuticals

Lexington, MA (Hybrid)Full time$230K/yr – $240K/yr
Kiniksa Pharmaceuticals logo
1 month ago

Director, Omnichannel Digital Marketing

Kiniksa Pharmaceuticals

Lexington, MA (Hybrid)Full time$230K/yr – $240K/yr
Kiniksa Pharmaceuticals logo
4 months ago

Director, HCP Marketing - US

Kiniksa Pharmaceuticals

Lexington, MA (Hybrid)Full time$225K/yr – $235K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Kiniksa Pharmaceuticals logo

Senior Manager, Marketing Operations

Kiniksa Pharmaceuticals

Lexington, MA (On-site)

$175K/yr - $195K/yrIn-houseFull-timeSenior level2+ years exp.
3 weeks ago
Kiniksa Pharmaceuticals logo

Associate Director, Digital Marketing

Kiniksa Pharmaceuticals

Lexington, MA (On-site)

$175K/yr - $195K/yrIn-houseFull-timeSenior level8+ years exp.
3 weeks ago
Kiniksa Pharmaceuticals logo

Director, Omnichannel & Marketing Capabilities/AI

Kiniksa Pharmaceuticals

Lexington, MA (Hybrid)

$230K/yr - $240K/yrIn-houseFull-timeDirector/executive10+ years exp.
1 month ago
Kiniksa Pharmaceuticals logo

Director, Omnichannel Digital Marketing

Kiniksa Pharmaceuticals

Lexington, MA (Hybrid)

$230K/yr - $240K/yrIn-houseFull-timeDirector/executive10+ years exp.
1 month ago
Kiniksa Pharmaceuticals logo

Director, HCP Marketing - US

Kiniksa Pharmaceuticals

Lexington, MA (Hybrid)

$225K/yr - $235K/yrIn-houseFull-timeDirector/executive7+ years exp.
4 months ago
Kiniksa Pharmaceuticals logo
Kiniksa Pharmaceuticals

Senior Manager, Marketing Operations

Lexington, MA (On-site)

$175K/yr – $195K/yrSenior Level2+ years expFull time

Posted 3 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own speaker bureau operations and governance from vendor management through compliance, with a focus on process efficiency, data interfaces, and cross-functional material review.

  • Speaker bureau operations, vendor management, and program logistics.
  • Promotional material review planning, cross-functional partnering, and regulatory compliance.
  • Data interfaces, PromoMats/Veeva usage, and internal training for data and process enhancements.

Job Description

Responsibilities
  • Manage vendor for speaker bureau operations, management, and program logistics
  • Develop and deliver regular communications with the brand teams, including reports reflecting their respective speaker program activity, spend, and achievement of objectives
  • Support development and execution of peer-to-peer strategy, including content creation and program development
  • Manage planning and development of annual speaker bureau training seminars
  • Support Kiniksa staff training related to speaker program operations and execution
  • Work with IT team and the speaker program / promotional material procurement suppliers on data interfaces and data management for internal data enhancements or changes
  • Partner with the Compliance team to ensure appropriate and accurate transparency reporting, adherence to relevant Kiniksa policies/processes, and ensure proper handling of any exceptions for the speaker bureau or program
  • Manage all aspects of the promotional material review process to ensure content and design are appropriate, accurate and consistent with all applicable regulations and laws and Kiniksa SOPs
  • Oversees regular promotional material review planning meetings to manage timely submissions and prioritization of agendas to meet business needs
  • Serve as a strategic partner with the medical, legal, and regulatory review team, marketing team, external agencies, and all cross-functional stakeholders involved in the promotional material review approval process to drive efficiency and compliance
Requirements
  • Bachelor’s degree with at least 2 years of experience in a pharmaceutical/biotech company, including 1+ years in Marketing Operations and/or project management roles
  • Proficient project management skills and attention to detail
  • Experience managing external vendors including establishing performance expectations, managing day-to-day activities, and ensuring appropriateness of work orders
  • Experience with Veeva PromoMats and Veeva Vault strongly preferred
  • Experience working with an external speakers’ bureau strongly desired
  • Interested in working in a fast-paced, innovative environment while remaining flexible, proactive, resourceful and efficient
  • Strong interpersonal skills, ability to develop important relationships with key stakeholders, good conflict management and negotiation skills
  • Strong project management and operational efficiency are critical
  • Demonstrates a strong ability to prioritize and multitask to enhance productivity and manage high volume workload in a fast-paced, rapidly changing environment
  • Ability to influence without authority across multi-functional teams with both internal and external stakeholders
Preferred
  • Experience with Veeva PromoMats and Veeva Vault strongly preferred
  • Experience working with an external speakers’ bureau strongly desired
  • Ability to influence without authority across multi-functional teams with both internal and external stakeholders
Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

3.4 Glassdoor

Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.At Kiniksa, patients are at the heart of everything we do. Our Every Second Counts! mindset reflects our commitment to making a difference for people who are navigating the uncertainty and challenges of life-altering diseases. This is why our team is relentless in pursuing treatments that bring us closer to a better future for patients, every second of every day.We rely on an exceptional team to drive our mission of building a global, generational company. If you're passionate about making a meaningful impact, we’d love to hear from you.Kiniksa offers competitive benefits and dynamic career opportunities across our organization. We foster a culture of passion, innovation, and rapid execution to help fulfill our mission.

Founded in 2015
Lexington, Massachusetts, USA
362 employees (10 in marketing)
www.kiniksa.com
45% recommend to a friend
48% CEO approval

Traffic Signals

Monthly Visitors
7K
Traffic Source Mix
Search
43%
Direct
41.8%
Referral
6.2%
Social
7.4%
Paid
1.4%

Headcount Trend

Current headcount: ~362

Marketing Team

Marketing Team Size
8 (2% of company)
Marketing Roles Posted (Last 30 Days)
2

Funding

Total Funding
$400M
Last Raise
$80M
Post IPO Equity, 6 years ago

Funding History

  • May 2020
    Post IPO Equity • $80M
  • Feb 2018
    Series C • $200M
  • Mar 2017
    Series B • $40M

Recent News

Kiniksa Pharma CFO Ragosa sells shares worth $1.77m
Dec 10, 2025 • Investing.com India
Jump Financial LLC Takes Position in Kiniksa Pharmaceuticals International, plc $KNSA
Dec 10, 2025 • MarketBeat
Understanding the Setup: (KNSA) and Scalable Risk
Dec 10, 2025 • news.stocktradersdaily.com
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Walleye Capital LLC
Dec 8, 2025 • MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA
Dec 8, 2025 • MarketBeat
Fisher Asset Management LLC Has $2.83 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA
Dec 6, 2025 • MarketBeat
Wedbush Reiterates Outperform Rating for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)
Dec 4, 2025 • MarketBeat
Traders Buy High Volume of Call Options on Kiniksa Pharmaceuticals International (NASDAQ:KNSA)
Dec 3, 2025 • MarketBeat
Franklin Resources Inc. Acquires 41,632 Shares of Kiniksa Pharmaceuticals International, plc $KNSA
Dec 3, 2025 • MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High - Time to Buy?
Nov 27, 2025 • MarketBeat
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript
Nov 27, 2025 • The Globe and Mail
Kiniksa Pharmaceuticals stock hits all-time high at 42.95 USD By Investing.com
Nov 26, 2025 • Investing.com UK
200,574 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by Hillsdale Investment Management Inc.
Nov 23, 2025 • MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 12,470 Shares of Stock
Nov 20, 2025 • MarketBeat
Kiniksa Pharma COO Tessari sells shares worth $514,224
Nov 19, 2025 • Investing.com
Los Angeles Capital Management LLC Sells 36,570 Shares of Kiniksa Pharmaceuticals International, plc $KNSA
Nov 19, 2025 • MarketBeat
Kiniksa Pharmaceuticals stock hits all-time high of 42.11 USD
Nov 18, 2025 • Investing.com
Savant Capital LLC Invests $398,000 in Kiniksa Pharmaceuticals International, plc $KNSA
Nov 18, 2025 • MarketBeat
Kiniksa at Jefferies London: Strategic Expansion and Financial Growth
Nov 17, 2025 • Investing.com
Kiniksa Rides ARCALYST Growth To Outpace The S&P 500
Nov 16, 2025 • Finimize
Mark Ragosa Sells 19,900 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock
Nov 16, 2025 • MarketBeat
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
Nov 12, 2025 • GlobeNewswire
Developing predictive dashboards with Kiniksa Pharmaceuticals Ltd. data - July 2025 Update & Consistent Return Strategy Ideas
Nov 9, 2025 • newser.com
Fox Run Management L.L.C. Buys 24,391 Shares of Kiniksa Pharmaceuticals International, plc $KNSA
Nov 9, 2025 • MarketBeat
Signal strength of Kiniksa Pharmaceuticals Ltd. stock in tech scanners - 2025 AllTime Highs & Weekly Top Gainers Trade List
Nov 9, 2025 • newser.com
Will Kiniksa Pharmaceuticals Ltd. stock benefit from sector rotation - Market Growth Summary & Breakout Confirmation Alerts
Nov 9, 2025 • newser.com
Automated trading signals detected on Kiniksa Pharmaceuticals Ltd. - Earnings Growth Report & Consistent Profit Trading Strategies
Nov 9, 2025 • newser.com
How to escape a deep drawdown in Kiniksa Pharmaceuticals Ltd. - July 2025 Institutional & Low Risk Entry Point Tips
Nov 9, 2025 • newser.com
Is Kiniksa’s Upbeat 2025 Sales Outlook Reshaping the Investment Case for KNSA?
Nov 9, 2025 • simplywall.st
Relative strength of Kiniksa Pharmaceuticals Ltd. in sector analysis - July 2025 Snapshot & AI Powered Trade Plan Recommendations
Nov 7, 2025 • newser.com
Custom watchlist performance reports with Kiniksa Pharmaceuticals Ltd. - Portfolio Performance Report & Reliable Intraday Trade Plans
Nov 7, 2025 • newser.com
How to escape a deep drawdown in Kiniksa Pharmaceuticals Ltd. - Swing Trade & Real-Time Volume Trigger Notifications
Nov 7, 2025 • newser.com
Vanguard Group Inc Reduces Stake in Kiniksa Pharmaceuticals Inte
Nov 7, 2025 • GuruFocus
Kiniksa Pharmaceuticals Ltd. stock chart pattern explained - Quarterly Earnings Report & High Accuracy Trade Alerts
Nov 6, 2025 • newser.com
Is Kiniksa Pharmaceuticals Ltd. building a consolidation base - 2025 Growth vs Value & Reliable Breakout Forecasts
Nov 6, 2025 • newser.com
John Paolini Sells 82,542 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock
Nov 6, 2025 • MarketBeat
Will Kiniksa Pharmaceuticals Ltd. stock benefit from sector rotation - July 2025 Weekly Recap & Fast Gain Stock Trading Tips
Nov 5, 2025 • newser.com
Will Kiniksa Pharmaceuticals Ltd. stock benefit from sector rotation - Analyst Upgrade & Daily Profit Focused Stock Screening
Nov 5, 2025 • newser.com
Can Kiniksa Pharmaceuticals Ltd. stock reach $100 price target - Forecast Cut & Weekly Setup with ROI Potential
Nov 5, 2025 • newser.com
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS
Nov 5, 2025 • MarketBeat
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve
Nov 5, 2025 • Yahoo Finance
Is Kiniksa Pharmaceuticals Ltd. stock ready for a breakout - 2025 Dividend Review & Free Expert Verified Stock Movement Alerts
Nov 5, 2025 • newser.com
Kiniksa Pharmaceuticals (KNSA): Valuation Insights Following Upgraded 2025 Sales Guidance and Profitability Shift
Nov 4, 2025 • simplywall.st
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts
Nov 4, 2025 • MarketBeat
Y Intercept Hong Kong Ltd Buys New Holdings in Kiniksa Pharmaceuticals International, plc $KNSA
Nov 2, 2025 • MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Rating Lowered by Wall Street Zen
Nov 2, 2025 • MarketBeat
The Bull Case For Kiniksa Pharmaceuticals (KNSA) Could Change Following ARCALYST Sales Surge and Return to Profitability
Oct 31, 2025 • Sahm
The Bull Case For Kiniksa Pharmaceuticals (KNSA) Could Change Following ARCALYST Sales Surge and Return to Profitability
Oct 31, 2025 • simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $55.00 at The Goldman Sachs Group
Oct 30, 2025 • MarketBeat
Kiniksa Pharmaceuticals (KNSA) Profit Surge Challenges Valuation Caution as Growth Outpaces Peers
Oct 30, 2025 • simplywall.st
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage
Oct 30, 2025 • Seeking Alpha
Kiniksa Pharmaceuticals (KNSA) Profit Surge Challenges Valuation Caution as Growth Outpaces Peers
Oct 30, 2025 • Sahm
Kiniksa Pharmaceuticals International's (KNSA) "Outperform" Rating Reaffirmed at Wedbush
Oct 29, 2025 • MarketBeat
Why Kiniksa Pharmaceuticals Shares Are Sliding
Oct 29, 2025 • TipRanks
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Q3 Growth, Profitability Surge, and New Orphan Drug News
Oct 28, 2025 • Sahm
Earnings call transcript: Kiniksa Pharmaceuticals Q3 2025 revenue surge boosts stock
Oct 28, 2025 • Investing.com Nigeria
Kiniksa Ramps Up Revenue Forecast As ARCALYST Gains Traction
Oct 28, 2025 • Finimize
Peregrine Capital Management LLC Trims Holdings in Kiniksa Pharmaceuticals International, plc $KNSA
Oct 28, 2025 • MarketBeat
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win
Oct 28, 2025 • Yahoo Finance
Kiniksa Pharmaceuticals: Strong Q3 Performance and Growth Potential Justify Buy Rating
Oct 28, 2025 • TipRanks
Earnings call transcript: Kiniksa Pharmaceuticals Q3 2025 revenue surge boosts stock
Oct 28, 2025 • Investing.com
Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis
Oct 27, 2025 • TipRanks
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
Oct 23, 2025 • GlobeNewswire
Kiniksa (Nasdaq: KNSA) sets Oct 28 8:30 a.m. ET webcast for third‑quarter results
Oct 23, 2025 • Stock Titan
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 97,390 Shares of Stock
Oct 23, 2025 • MarketBeat
Kiniksa Pharma CEO Patel sells $10 million in shares
Oct 22, 2025 • Investing.com
Kiniksa Pharmaceuticals stock hits all-time high at 39.46 USD
Oct 20, 2025 • Investing.com
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High Following Analyst Upgrade
Oct 20, 2025 • MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $50.00 at Citigroup
Oct 18, 2025 • MarketBeat
Kiniksa Pharmaceuticals (KNSA) Sees 11% Increase in Citigroup's Price Target | KNSA Stock News
Oct 17, 2025 • GuruFocus
FDA grants orphan drug designation to Kiniksa’s pericarditis treatment
Oct 17, 2025 • Investing.com
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Oct 17, 2025 • GlobeNewswire
Kiniksa Pharmaceuticals Stock Surges on FDA News
Oct 17, 2025 • TipRanks
Kiniksa Pharmaceuticals Receives Orphan Drug Designation from FDA for KPL-387 in Treating Pericarditis
Oct 17, 2025 • Quiver Quantitative
FDA Orphan Drug Designation: KPL-387 by Kiniksa for Pericarditis; Phase 2 Data Expected H2 2026
Oct 17, 2025 • Stock Titan
Kiniksa Pharma COO Tessari sells $465,843 in shares
Oct 16, 2025 • Investing.com
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again
Oct 16, 2025 • Yahoo Finance
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet
Oct 14, 2025 • Yahoo Finance
Kiniksa Pharmaceuticals (KNSA): Valuation in Focus Following Upbeat 2025 Revenue Guidance and Arcalyst Growth Momentum
Oct 14, 2025 • Sahm
Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $44
Oct 13, 2025 • 富途牛牛
Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price
Oct 13, 2025 • MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 1-Year High - Still a Buy?
Oct 10, 2025 • MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Earns Hold (C) Rating from Weiss Ratings
Oct 10, 2025 • MarketBeat
Looking at the Narrative for Kiniksa Pharmaceuticals as Analyst Optimism Grows with Arcalyst Momentum
Oct 10, 2025 • Yahoo Finance
Kiniksa Pharmaceuticals stock hits all-time high at 39.15 USD
Oct 9, 2025 • Investing.com
Robeco Institutional Asset Management B.V. Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA
Oct 9, 2025 • MarketBeat
Will Kiniksa’s 92% 2024 Surge Continue After Strong Cash Flow Growth?
Oct 9, 2025 • simplywall.st
Kiniksa Pharmaceuticals International, plc $KNSA Stock Position Reduced by Knights of Columbus Asset Advisors LLC
Oct 8, 2025 • MarketBeat
Are Executive Stock Sales at Kiniksa (KNSA) Changing the Narrative on Management Confidence?
Oct 7, 2025 • simplywall.st
Wealth Enhancement Advisory Services LLC Has $430,000 Stake in Kiniksa Pharmaceuticals International, plc $KNSA
Oct 7, 2025 • Defense World
Here's What Could Help Kiniksa Pharmaceuticals International, plc (KNSA) Maintain Its Recent Price Strength
Oct 6, 2025 • Yahoo Finance
Here's What Could Help Kiniksa Pharmaceuticals International, plc (KNSA) Maintain Its Recent Price Strength
Oct 6, 2025 • sharewise.com
Wall Street Zen Downgrades Kiniksa Pharmaceuticals International (NASDAQ:KNSA) to Buy
Oct 5, 2025 • Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street Zen
Oct 4, 2025 • MarketBeat
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After a Year of Strong Share Price Growth
Oct 3, 2025 • Sahm
AMI Asset Management Corp Sells 34,547 Shares of Kiniksa Pharmaceuticals International, plc $KNSA
Oct 2, 2025 • MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 42,000 Shares of Stock
Oct 1, 2025 • MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Now Covered by TD Cowen
Sep 30, 2025 • Defense World
Kiniksa stock initiated with Buy rating at TD Cowen on Arcalyst growth potential
Sep 29, 2025 • Investing.com UK
Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
Sep 29, 2025 • TipRanks